Julie O'Neal, PhD

Department of Medicine
Oncology Division
Stem Cell Biology

Research Interests

  • CAR-T therapy for multiple myeloma
  • Novel therapeutics for multiple myeloma
  • Genomics and biology of multiple myeloma


  • 314-362-9335 (tel)
  • 314-362-9333 (fax)
  • Room 626P, Southwest Tower (office)
  • Washington University School of Medicine
    Division of Oncology
    Campus Box 8007
    660 South Euclid Avenue
    St. Louis, MO 63110


Although outcomes for multiple myeloma have improved, most patients die from relapsed disease. My research focus is to further our understanding of the biology of multiple myeloma so we can use new information to better identify, design, and test novel therapies that will improve outcomes of myeloma patients. Chimeric Antigen Receptor (CAR) proteins are hybrid proteins expressed on T cells (CAR-T) that kill cells expressing a specific target protein on their surface. We are using preclinical myeloma models to test efficacy of tumor cells (CAR-T) with the goal to generate a CAR product that will be used to effectively cure myeloma patients. In addition to a panel of targets already being tested, we are using expression and proteomic analysis to identify novel myeloma CAR targets. We are also exploring other immune cell types that may prove useful for expressing CAR proteins and killing tumor cells. We are also testing small molecule compounds alone or packaged in nanoparticles for efficacy in myeloma.